New FDA Leadership Appointed
Trump administration permanently appoints four key leaders to rebuild troubled food and drug administration.
Anonymous
Key Points
1
Michael Davis had served as the Center for Drug Evaluation and Research’s deputy director for about a year before becoming its acting director in May, while Karim Mikhail had worked at the FDA as an adviser before taking over as acting head of the biologics center.
2
The FDA has lost more than 3,000 employees over the past year, including division heads, as it tries to restore confidence among pharmaceutical companies and public-health organizations.
3
The agency’s staffing crisis intensified after Health Secretary Robert F. Kennedy Jr. fired thousands of employees across the Department of Health and Human Services, contributing to declining morale and an exodus of senior experts.
4
The administration plans to have two FDA deputy commissioners: one responsible for technology, including health care and artificial intelligence, and another overseeing drugs.
5
The FDA’s centers for drug and biologics review oversee medicines, vaccines and other biological products, underscoring the importance of the newly permanent appointments to the agency’s core regulatory work.
The Trump administration has permanently filled four key leadership roles at the Food and Drug Administration, solidifying its restructuring of the troubled agency. Pharma Voice reported that Michael Davis will lead the Center for Drug Evaluation and Research, while Karim Mikhail heads the Center for Biologics Evaluation and Research. The appointments follow months of upheaval as the FDA works to restore confidence after losing more than 3,000 employees in the past year.
The administration also named Bret Koplow to direct the Center for Tobacco Products and created a new position: Jared Seehafer as the FDA's first deputy commissioner for technology and artificial intelligence. HHSannounced these moves as part of a broader push to use AI to speed up regulatory reviews and rebuild the agency's workforce after staff departures and low morale.
Permanent Leaders End Months of Acting Transitions
Michael Davis and Karim Mikhail move from acting roles to permanent positions after serving in leadership during the FDA's transition period. Pharma Voice noted that Davis had worked as deputy director of the drug center for about a year before taking the acting role in May. Mikhail previously served as an FDA adviser before stepping into the acting position at the biologics center.
These permanentappointments bring stability to the FDA's two largest regulatory centers. The drug and biologics centers oversee medicines, vaccines, and other biological products that millions of Americans depend on. Permanent leadership signals the agency is ready to rebuild trust with pharmaceutical companies and public-health organizations.
FDA's Massive Staff Exodus Creates Urgent Staffing Crisis
The FDA has shed more than 3,000 employees over the past year, including senior division heads and experienced regulators. HHS has highlighted this exodus as a critical challenge facing the agency. The departures created dangerous gaps in expertise across departments responsible for reviewing new drugs and vaccines.
Health Secretary Robert F. Kennedy Jr. fired thousands of workers across the Department of Health and Human Services, intensifying the FDA's staffing crisis and draining morale. Experienced staff left voluntarily as well, taking institutional knowledge with them. The agency now faces the dual task of filling positions and rebuilding relationships with industry and the public.
New AI Deputy Commissioner Reflects Regulatory Modernization Push
Jared Seehafer's appointment as the FDA's first deputy commissioner for technology and artificial intelligence represents a major shift in the agency's approach. HHS emphasized that this new role will oversee how the FDA uses AI to accelerate regulatory reviews and modernize its processes. The position reflects growing recognition that AI tools can speed up drug approval timelines.
The administration plans to have two FDA deputy commissioners: one overseeing technology and AI, and another responsible for drugs. This structure gives technology equal weight with core regulatory functions. It signals the Trump administration's commitment to using digital tools and AI to reduce bureaucracy and speed medical innovation.
Rebuilding Confidence After Vaccine and Drug Approval Disputes
The FDA faced intense criticism over vaccine policies, abortion-pill approvals, and drug-approval decisions that divided staff and eroded public trust. WHEC reported that these disputes contributed to the agency's troubled transition period. Permanent leadership appointments aim to establish clear direction and end months of uncertainty about the agency's priorities.
Restoring confidence among pharmaceutical companies is essential for the FDA's regulatory work. Companies need to know the agency has stable leadership and clear standards for approval. These four appointments represent the administration's attempt to move past the turbulent period and establish a more predictable regulatory environment.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
193
Reach
212
A
AnonymousAuthor
